On September 8, 2022 Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to elicit a potent and durable immune response in the tumor microenvironment, reported that it will host a virtual webinar to review the latest clinical trial data for BCA101, a first-in-class EGFR/TGFβ-trap bifunctional antibody designed to deliver superior anti-tumor efficacy with an improved therapeutic window to solid tumors (Press release, Bicara Therapeutics, SEP 8, 2022, View Source;utm_medium=rss&utm_campaign=bicara-therapeutics-to-host-webinar-to-review-latest-clinical-trial-data-for-bca101 [SID1234619242]). The webinar will be held Monday, September 12, 2022 at 10:30 a.m. ET.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During the webinar, Dr. Glenn Hanna, principal investigator from Dana-Farber Cancer Institute, will review the Phase 1 data presented at the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2022. Management will then discuss the development program in more detail, followed by a Q&A session. Presenters for the event are:
Claire Mazumdar, Ph.D., Chief Executive Officer, Bicara Therapeutics
Glenn J. Hanna, M.D., Director of the Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute and Principal Investigator in the Phase 1 trial for BCA101
Liviu Niculescu, M.D., Chief Medical Officer, Bicara Therapeutics
To register for the live event, please visit the Online Experiences website. Following the live webcast, an archived replay will be available on the Company’s website, www.Bicara.com.
About BCA101
BCA101 is a first-in-class EGFR / TGF-β-trap bifunctional antibody designed to enhance both innate and adaptive immune responses directly at the site of the tumor by binding to the well-validated EGFR antigen and disabling TGF-β, a signaling molecule that plays a key role in suppressing the immune response in the tumor microenvironment. Promising preclinical data suggest that BCA101 is superior to the anti-EGFR antibody cetuximab in preventing tumor recurrence, as well as in restoring immune activation. An ongoing Phase 1/1b clinical trial of BCA101, initiated in July 2020, has enrolled cohorts of patients in a dose-escalation study with BCA101 as a single agent, as well as in combination with pembrolizumab, a PD-1 inhibitor and a recommended dose for expansion has been declared. Enrollment in the dose expansion arm of the study in first-line head and neck in combination with pembrolizumab is currently ongoing. For more information, please visit study number NCT04429542 at www.clinicaltrials.gov.